KIF2C promotes the proliferation of hepatocellular carcinoma cells in vitro and in vivo
- Zhenya Gao
- Huanxia Jia
- Fang Yu
- Hongfang Guo
- Baoyu Li
Affiliations: Department of Clinical Medicine, School of Medicine, Xuchang University, Xuchang, Henan 461000, P.R. China, Department of General Surgery, The Secondary Hospital of Tianjin Medical University, Tianjin 300211, P.R. China
- Published online on: August 2, 2021 https://doi.org/10.3892/etm.2021.10528
Copyright: © Gao
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Hepatocellular carcinoma (HCC) is one of the most common malignancies with high mortality and morbidity rates. In recent years, HCC targeted therapy has gained increasing attention. Due to the heterogeneity and high metastasis of HCC, more effective therapeutic targets are needed. Kinesin family member 2C (KIF2C), also known as mitotic centromere‑associated kinesin, is a microtubule‑based motor protein which is involved in a variety of important cellular processes, such as mitosis. The effects of KIF2C on cancer progression and development have been widely studied; however, its potential effects on HCC remains unclear. In the present study, high expression of KIF2C in human HCC tissues was demonstrated using The Cancer Genome Atlas database and immunohistochemistry assays. KIF2C expression was associated with HCC prognosis, including overall survival and disease‑free survival. KIF2C expression was also associated with clinical pathological characteristics including the number of tumor nodes (P=0.015) and tumor size (P=0.009). KIF2C knockdown inhibited the proliferation of HCC cells in vitro, confirmed by MTT and colony formation assays, and suppressed tumor growth in mice which was confirmed by a xenograft mouse model. Together, the results suggested that KIF2C may serve as a promising therapeutic target for the treatment of HCC.